BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 21428449)

  • 1. Small molecule inhibitors of retinoic acid 4-hydroxylase (CYP26): synthesis and biological evaluation of imidazole methyl 3-(4-(aryl-2-ylamino)phenyl)propanoates.
    Gomaa MS; Bridgens CE; Aboraia AS; Veal GJ; Redfern CP; Brancale A; Armstrong JL; Simons C
    J Med Chem; 2011 Apr; 54(8):2778-91. PubMed ID: 21428449
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and biological evaluation of 3-(1H-imidazol- and triazol-1-yl)-2,2-dimethyl-3-[4-(naphthalen-2-ylamino)phenyl]propyl derivatives as small molecule inhibitors of retinoic acid 4-hydroxylase (CYP26).
    Gomaa MS; Bridgens CE; Veal GJ; Redfern CP; Brancale A; Armstrong JL; Simons C
    J Med Chem; 2011 Oct; 54(19):6803-11. PubMed ID: 21838328
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel azolyl-(phenylmethyl)]aryl/heteroarylamines: potent CYP26 inhibitors and enhancers of all-trans retinoic acid activity in neuroblastoma cells.
    Gomaa MS; Armstrong JL; Bobillon B; Veal GJ; Brancale A; Redfern CP; Simons C
    Bioorg Med Chem; 2008 Sep; 16(17):8301-13. PubMed ID: 18722776
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel retinoic acid 4-hydroxylase (CYP26) inhibitors based on a 3-(1H-imidazol- and triazol-1-yl)-2,2-dimethyl-3-(4-(phenylamino)phenyl)propyl scaffold.
    Gomaa MS; Bridgens CE; Illingworth NA; Veal GJ; Redfern CP; Brancale A; Armstrong JL; Simons C
    Bioorg Med Chem; 2012 Jul; 20(14):4201-7. PubMed ID: 22727372
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design and synthesis of substituted imidazole and triazole N-phenylbenzo[d]oxazolamine inhibitors of retinoic acid metabolizing enzyme CYP26.
    Pautus S; Aboraia AS; Bassett CE; Brancale A; Coogan MP; Simons C
    J Enzyme Inhib Med Chem; 2009 Apr; 24(2):487-98. PubMed ID: 18608743
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and CYP26A1 inhibitory activity of novel methyl 3-[4-(arylamino)phenyl]-3-(azole)-2,2-dimethylpropanoates.
    Gomaa MS; Lim AS; Lau SC; Watts AM; Illingworth NA; Bridgens CE; Veal GJ; Redfern CP; Brancale A; Armstrong JL; Simons C
    Bioorg Med Chem; 2012 Oct; 20(20):6080-8. PubMed ID: 22989911
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and CYP26A1 inhibitory activity of 1-[benzofuran-2-yl-(4-alkyl/aryl-phenyl)-methyl]-1H-triazoles.
    Pautus S; Yee SW; Jayne M; Coogan MP; Simons C
    Bioorg Med Chem; 2006 Jun; 14(11):3643-53. PubMed ID: 16458519
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis, and biological evaluation of amide imidazole derivatives as novel metabolic enzyme CYP26A1 inhibitors.
    Sun B; Liu K; Han J; Zhao LY; Su X; Lin B; Zhao DM; Cheng MS
    Bioorg Med Chem; 2015 Oct; 23(20):6763-73. PubMed ID: 26365710
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular targeting of retinoic acid metabolism in neuroblastoma: the role of the CYP26 inhibitor R116010 in vitro and in vivo.
    Armstrong JL; Taylor GA; Thomas HD; Boddy AV; Redfern CP; Veal GJ
    Br J Cancer; 2007 Jun; 96(11):1675-83. PubMed ID: 17486130
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Substrate specificity and ligand interactions of CYP26A1, the human liver retinoic acid hydroxylase.
    Thatcher JE; Buttrick B; Shaffer SA; Shimshoni JA; Goodlett DR; Nelson WL; Isoherranen N
    Mol Pharmacol; 2011 Aug; 80(2):228-39. PubMed ID: 21521770
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development and Characterization of Novel and Selective Inhibitors of Cytochrome P450 CYP26A1, the Human Liver Retinoic Acid Hydroxylase.
    Diaz P; Huang W; Keyari CM; Buttrick B; Price L; Guilloteau N; Tripathy S; Sperandio VG; Fronczek FR; Astruc-Diaz F; Isoherranen N
    J Med Chem; 2016 Mar; 59(6):2579-95. PubMed ID: 26918322
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel retinoic acid metabolism blocking agents endowed with multiple biological activities are efficient growth inhibitors of human breast and prostate cancer cells in vitro and a human breast tumor xenograft in nude mice.
    Patel JB; Huynh CK; Handratta VD; Gediya LK; Brodie AM; Goloubeva OG; Clement OO; Nanne IP; Soprano DR; Njar VC
    J Med Chem; 2004 Dec; 47(27):6716-29. PubMed ID: 15615521
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel tetralone-derived retinoic acid metabolism blocking agents: synthesis and in vitro evaluation with liver microsomal and MCF-7 CYP26A1 cell assays.
    Yee SW; Jarno L; Gomaa MS; Elford C; Ooi LL; Coogan MP; McClelland R; Nicholson RI; Evans BA; Brancale A; Simons C
    J Med Chem; 2005 Nov; 48(23):7123-31. PubMed ID: 16279770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and biological evaluation of 3-phenyl-3-aryl carboxamido propanoic acid derivatives as small molecule inhibitors of retinoic acid 4-hydroxylase (CYP26A1).
    Zhao D; Sun B; Ren J; Li F; Song S; Lv X; Hao C; Cheng M
    Bioorg Med Chem; 2015 Mar; 23(6):1356-65. PubMed ID: 25684424
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 3-[6-(2-Dimethylamino-1-imidazol-1-yl-butyl)-naphthalen-2-yloxy]-2,2-dimethyl-propionic acid as a highly potent and selective retinoic acid metabolic blocking agent.
    Mulvihill MJ; Kan JL; Cooke A; Bhagwat S; Beck P; Bittner M; Cesario C; Keane D; Lazarescu V; Nigro A; Nillson C; Panicker B; Smith V; Srebernak M; Sun FL; O'Connor M; Russo S; Fischetti G; Vrkljan M; Winski S; Castelhano AL; Emerson D; Gibson NW
    Bioorg Med Chem Lett; 2006 May; 16(10):2729-33. PubMed ID: 16504501
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 2-(2-Methylfuran-3-carboxamido)-3-phenylpropanoic acid, a potential CYP26A1 inhibitor to enhance all-trans retinoic acid-induced leukemia cell differentiation based on virtual screening and biological evaluation.
    Li F; Zhao D; Ren J; Hao F; Liu G; Jin S; Jing Y; Cheng M
    Bioorg Med Chem; 2013 Jun; 21(11):3256-61. PubMed ID: 23601821
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potent and selective [2-imidazol-1-yl-2-(6-alkoxy-naphthalen-2-yl)-1-methyl-ethyl]-dimethyl-amines as retinoic acid metabolic blocking agents (RAMBAs).
    Mulvihill MJ; Kan JL; Beck P; Bittner M; Cesario C; Cooke A; Keane DM; Nigro AI; Nillson C; Smith V; Srebernak M; Sun FL; Vrkljan M; Winski SL; Castelhano AL; Emerson D; Gibson N
    Bioorg Med Chem Lett; 2005 Mar; 15(6):1669-73. PubMed ID: 15745819
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytochrome p450 retinoic acid 4-hydroxylase inhibitors: potential agents for cancer therapy.
    Njar VC
    Mini Rev Med Chem; 2002 Jun; 2(3):261-9. PubMed ID: 12370067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. all-trans-Retinoic acid-induced expression and regulation of retinoic acid 4-hydroxylase (CYP26) in human promyelocytic leukemia.
    Ozpolat B; Mehta K; Tari AM; Lopez-Berestein G
    Am J Hematol; 2002 May; 70(1):39-47. PubMed ID: 11994980
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis, biochemical evaluation and rationalisation of the inhibitory activity of a range of phenyl alkyl imidazole-based compounds as potent inhibitors of the enzyme complex 17alpha-hydroxylase/17,20-lyase (P450(17alpha)).
    Owen CP; Shahid I; Olusanjo MS; Patel CH; Dhanani S; Ahmed S
    J Steroid Biochem Mol Biol; 2008 Jul; 111(1-2):117-27. PubMed ID: 18620055
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.